NAS:PTLA (USA) Also trade in: Germany

Portola Pharmaceuticals Inc

$ 30.44 0.96 (3.26%)
Volume: 1,079,104 Avg Vol (1m): 1,128,509
Market Cap $: 2.07 Bil Enterprise Value $: 2.03 Bil
P/E (TTM): 0.00 P/B: 42.19
Earnings Power Value -57.86
Net Current Asset Value 0.04
Tangible Book 0.62
Projected FCF -39.86
Median P/S Value 66.19
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.17
Cash-To-Debt ranked lower than
71.89% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
PTLA: 1.17
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.17, Med: 10000, Max: 10000
Current: 1.17
1.17
10000
Equity-to-Asset 0.12
Equity-to-Asset ranked lower than
76.80% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
PTLA: 0.12
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.31, Med: 0.77, Max: 0.91
Current: 0.12
-1.31
0.91
Debt-to-Equity 5.69
Debt-to-Equity ranked lower than
82.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
PTLA: 5.69
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.25, Med: 0.76, Max: 5.69
Current: 5.69
0.25
5.69
Debt-to-EBITDA -0.87
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
PTLA: -0.87
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.87, Med: -0.39, Max: -0.19
Current: -0.87
-0.87
-0.19
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.82
DISTRESS
GREY
SAFE
Beneish M-Score -0.07
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 18.76%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -599.44
Operating Margin ranked lower than
79.42% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
PTLA: -599.44
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1882.15, Med: -799.34, Max: 25.46
Current: -599.44
-1882.15
25.46
Net Margin % -618.45
Net Margin ranked lower than
79.92% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
PTLA: -618.45
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1876.59, Med: -791.49, Max: 25.61
Current: -618.45
-1876.59
25.61
ROE % -208.12
ROE ranked lower than
80.69% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
PTLA: -208.12
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -208.12, Med: -96.78, Max: -42.58
Current: -208.12
-208.12
-42.58
ROA % -76.70
ROA ranked lower than
76.01% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
PTLA: -76.7
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -76.7, Med: -43.11, Max: 20.67
Current: -76.7
-76.7
20.67
ROC (Joel Greenblatt) % -6196.80
ROC (Joel Greenblatt) ranked lower than
81.85% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
PTLA: -6196.8
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -6348.49, Med: -4564.5, Max: 1029.06
Current: -6196.8
-6348.49
1029.06
3-Year Total Revenue Growth Rate 49.30
3-Year Revenue Growth Rate ranked higher than
75.27% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
PTLA: 37.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -58.2, Med: -9.9, Max: 37.9
Current: 37.9
-58.2
37.9
3-Year Total EBITDA Growth Rate -13.30
3-Year EBITDA Growth Rate ranked lower than
68.45% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
PTLA: -4.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -45.55, Max: -4.6
Current: -4.6
0
-4.6
3-Year EPS w/o NRI Growth Rate -6.80
3-Year EPS w/o NRI Growth Rate ranked lower than
70.77% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
PTLA: -6.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -7.35, Max: -6.8
Current: -6.8
0
-6.8

» PTLA's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PTLA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:LGND NAS:RETA NAS:INSM XSWX:IDIA NAS:HALO SZSE:300009 XSWX:GALE NAS:DNLI TSE:4974 NAS:AKCA NAS:ARNA NAS:MYOK NAS:ICPT OSTO:VITR XBRU:TUB NAS:PTCT XKRX:086900 NAS:MRTX SHSE:600201 NYSE:EBS
Traded in other countries 0PP.Germany
Address 270 East Grand Avenue, South San Francisco, CA, USA, 94080
Portola Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Ratios

Current vs industry vs history
PB Ratio 42.19
PB Ratio ranked lower than
77.13% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
PTLA: 42.19
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.07, Med: 6.26, Max: 52.17
Current: 42.19
3.07
52.17
PS Ratio 36.38
PS Ratio ranked lower than
80.72% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
PTLA: 36.38
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 25.51, Med: 79.18, Max: 285.93
Current: 36.38
25.51
285.93
EV-to-EBIT -6.30
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
PTLA: -6.3
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -14.3, Med: -7.6, Max: -1.3
Current: -6.3
-14.3
-1.3
EV-to-EBITDA -6.36
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
PTLA: -6.36
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -14.4, Med: -7.6, Max: -1.3
Current: -6.36
-14.4
-1.3
EV-to-Revenue 36.41
EV-to-Revenue ranked lower than
76.26% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
PTLA: 36.41
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 10.3, Med: 77.7, Max: 261.8
Current: 36.41
10.3
261.8
Current Ratio 4.81
Current Ratio ranked higher than
64.15% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
PTLA: 4.81
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 4.81, Med: 7.32, Max: 10.67
Current: 4.81
4.81
10.67
Quick Ratio 4.77
Quick Ratio ranked higher than
64.34% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
PTLA: 4.77
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 4.77, Med: 7.32, Max: 10.67
Current: 4.77
4.77
10.67
Days Inventory 79.17
Days Inventory ranked lower than
92.31% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
PTLA: 79.17
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 79.17, Med: 286.93, Max: 483.3
Current: 79.17
79.17
483.3
Days Sales Outstanding 77.30
Days Sales Outstanding ranked higher than
63.32% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
PTLA: 77.3
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 2.16, Med: 10.71, Max: 77.3
Current: 77.3
2.16
77.3
Days Payable 142.92
Days Payable ranked lower than
97.76% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
PTLA: 142.92
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 142.92, Med: 4224.91, Max: 8183.04
Current: 142.92
142.92
8183.04

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.40
3-Year Share Buyback Rate ranked higher than
58.81% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
PTLA: -5.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -30.4, Med: -14.3, Max: -5.4
Current: -5.4
-30.4
-5.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 49.10
Price-to-Tangible-Book ranked lower than
71.36% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
PTLA: 49.1
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.14, Med: 6.63, Max: 56.33
Current: 49.1
3.14
56.33
Price-to-Median-PS-Value 0.46
Price-to-Median-PS-Value ranked higher than
61.06% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
PTLA: 0.46
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.41, Med: 0.99, Max: 2.83
Current: 0.46
0.41
2.83
Earnings Yield (Joel Greenblatt) % -15.84
Earnings Yield (Greenblatt) ranked lower than
71.23% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
PTLA: -15.84
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -76.3, Med: -13.2, Max: -7
Current: -15.84
-76.3
-7

More Statistics

Revenue (TTM) (Mil) $ 55.66
EPS (TTM) $ -5.2
Beta 2.82
Volatility % 60.3
52-Week Range $ 14.81 - 45.6
Shares Outstanding (Mil) 65.3

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y